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 2 
Abstract 18 
In the current study 43 pharmaceuticals and 18 transformation products were studied in the river 19 
Meuse at the Belgian-Dutch border and four tributaries of the river Meuse in the southern part of the 20 
Netherlands. The tributaries originate from Belgian, Dutch and mixed Dutch and Belgian catchments. In 21 
total, 24 pharmaceuticals and 13 transformation products were observed in samples of river water 22 
collected from these rivers. Observed summed concentrations of pharmaceuticals and transformation 23 
products in river water ranged from 3.5 to 37.8 µg/L. Metformin and its transformation product 24 
guanylurea contributed with 53 to 80 % to this concentration, illustrating its importance on a mass 25 
basis. Data on the flow rate of different rivers and demographics of the catchments enabled us to 26 
calculate daily per capita loads of pharmaceuticals and transformation products. These loads were 27 
linked to sales data of pharmaceuticals in the catchment. Simple mass balance modelling accounting for 28 
human excretion and removal by sewage treatment plants revealed that sales could predict actual 29 
loads within a factor three for most pharmaceuticals. Rivers that originated from Belgian and mixed 30 
Dutch and Belgian catchments revealed significantly higher per capita loads of pharmaceuticals (16.0 ± 31 
2.3 and 15.7 ± 2.1 mg/inhabitant/day, respectively) than the Dutch catchment (8.7 ± 1.8 32 
mg/inhabitant/day). Furthermore, the guanylurea /metformin ratio was significantly lower in waters 33 
originating from Belgium (and France) than in those from the Netherlands, illustrating that sewage 34 
treatment in the Belgian catchment is less efficient in transforming metformin into guanylurea. In 35 
summary, the current study shows that consumption based modeling is suitable to predict 36 
environmental loads and concentrations. Furthermore, different consumption patterns and wastewater 37 
treatment efficiency are clearly reflected in the occurrence and loads of pharmaceuticals in regional 38 
rivers.   39 
 3 
Introduction 40 
Numerous studies describe the presence of pharmaceuticals in the aqueous environment (Monteiro 41 
and Boxall, 2010; Roig, 2010). These pharmaceuticals can originate from human consumption, 42 
veterinary consumption, aquaculture or (accidental) emissions during production (Larsson et al., 2007) 43 
and transport of pharmaceuticals. Consumed human pharmaceuticals are excreted by humans via urine 44 
and feces. They are subsequently transported to sewage treatment facilities and are (partially) emitted 45 
to surface waters. However not all consumed pharmaceuticals end up in the environment since they 46 
can be metabolized in the human body . After excretion, pharmaceuticals and metabolites can be 47 
further transformed or sorbed in sewage systems, sewage treatment plants (active sludge) and 48 
receiving waters. The rates and nature of the metabolism, transformation and sorption depend on the 49 
chemical properties of the pharmaceutical  the physiology of the person using the medication and 50 
environmental conditions in wastewater treatment and receiving waters. While parent pharmaceuticals 51 
have been studied intensively in the environmental over the last decades metabolites and 52 
transformation products (later all referred to as transformation products) have drawn less attention in 53 
monitoring and risk assessment (Escher and Fenner, 2011). 54 
 55 
Databases on the sales of pharmaceuticals and extensive knowledge of excretion and metabolism, 56 
stability and sorption in commonly applied sewage treatment systems, and stability and sorption in 57 
receiving waters enables one to relate sales to loads in surface waters (Castiglioni et al., 2004; Liebig et 58 
al., 2006; Alder et al., 2010; ter Laak et al., 2010; Kugathas et al., 2012). Furthermore, pharmaceutical 59 
consumption varies between regions (Van den Berg Jeths and Van Batenburg-Eddes, 2003) and 60 
countries (Mossialos et al., 2004), while sewage treatment practice and environmental conditions differ 61 
between regions, countries (Boyjoo et al., 2013) and seasons (Sui et al., 2011). Regional consumption 62 
data and knowledge on sewage treatment practice can guide monitoring efforts in different regions, 63 
countries or seasons and define ‘hot spots’ where environmental risks are the highest. Furthermore, it 64 
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can be applied to model regional emissions and predict emissions under different consumption-, waste 65 
water treatment- and river discharge scenarios.   66 
 67 
The assessment of water quality for the ecosystem health and for drinking water production, can 68 
benefit from knowledge of  regional sources, emissions and occurrence of pharmaceuticals. 69 
Additionally, it can benefit from knowledge on the formation and occurrence of  transformation 70 
products. In the present work, three approaches are defined to gain knowledge and assess the fate and 71 
behaviour of pharmaceuticals and transformation products in the environment.   72 
 73 
First, ratios of pharmaceuticals and transformation products were studied in order to reveal whether 74 
ratios between parent compounds and their products are stable and might allow prediction of one 75 
concentration from the other. Ratios between different pharmaceuticals were not studied, but this 76 
might be of interest in future research. Secondly, the occurrence of pharmaceuticals and 77 
transformation products was studied and linked to available sales data to reveal whether sales data are 78 
suitable to predict loads in regional surface waters. Finally, the composition of pharmaceuticals in 79 
different rivers fed by sewage from Belgium and the Netherlands were qualitatively and quantitatively 80 
evaluated to reveal differences between countries.  81 
 82 
 5 
Material and method 83 
 84 
Sampling locations 85 
Samples were taken in the river Meuse catchment of the province of Limburg, the most southern 86 
province of the Netherlands (Figure 1). Water from the river Meuse was sampled near Eijsden where 87 
the river Meuse crosses the border between Belgium and the Netherlands. Four tributaries of the river 88 
Meuse i.e. the river Jeker, the river Geul and the river Geleenbeek and river Slijbeek (later referred to as 89 
the Jeker, Geul, Geleenbeek and Slijbeek) were sampled near the point where they flow into the river 90 
Meuse or into a channel that is connected to the river Meuse (i.e. Slijbeek).  91 
 92 
FIGURE 1 93 
 94 
Table 1 shows the median, minimum and maximum flow rates of the selected rivers. Furthermore, the 95 
number of sewage treatment plants discharging to the different waters and the number inhabitants of 96 
the catchments are listed. These data are used to predict loads of pharmaceuticals in the different 97 
waters and relate predicted loads to monitoring data. 98 
 99 
TABLE 1 100 
 101 
Each of the five locations was sampled in 2011 on November the 23rd, November the 30th, December 102 
the 7th and December the 12th 2011 between 9:00 and 13:00 by grab sampling. Water was collected in 103 
1000 mL ultra-clean dark green glass bottles and directly stored at 4°C for a maximum of 4 weeks. 104 
Further details can be found in Table S1, of Supplementary Information. Grab sampling was used 105 
because time integrated sampling was not feasible at the sampling locations. 106 
  107 
 6 
Pharmaceuticals and transformation products 108 
Samples were analysed for  43 pharmaceuticals and 18 transformation products. The pharmaceuticals 109 
were selected based on consumption, occurrence in the environment, physicochemical properties, their 110 
availability as standards and whether they can be analysed (de Voogt et al., 2009). Pharmaceuticals and 111 
transformation products were obtained from Sigma Aldrich, AK Scientific, Frinton Laboratories and 112 
CHEMOS. The purity of the chemicals was > 97 %, except for clindamycin (88.3 %), erythromycin (95 %) 113 
and N-acetyl-4-aminoantipyrine (97 %). Deuterated (internal) standards (Atenolol-d7, Atrazine-d5, 114 
Bentazone-d6,  Benzotriazool-d4, Carbamazepine-d10, Fluoxetine-d5, Gemfibrozil-d6, Metformin-d6, 115 
Paracetamol-d3, Phenazone-d3 and Sulfamethoxazole-d4) were obtained from CDN Isotopes. Detailed 116 
information on the pharmaceuticals studied is listed in Table S2 of the Supplementary Information. 117 
 118 
Analysis of pharmaceuticals and transformation products in water 119 
Aqueous samples were filtered over a 0.20 µm regenerated cellulose filter (Whatman, Spartan 120 
30/B). 100 µL of the filtrated water samples (spiked with 0.5 µg/L internal standards) were 121 
directly injected on a Thermo Scientific TSQ Vantage LC-MS/MS equipped with an Accela 122 
autosampler and pump. The LC system was equipped with either a reversed phase column, i.e. 123 
a 100x2.1 mm Hypersil Gold column with a particle size of 1.9 µm (Thermo Scientific) or with a 124 
ZIC HILIC column, i.e. a 100x2.1mm ZIC-HILIC column with 3.5 µm particle size. The 125 
temperature of the columns was held constant at 25 °C. An ESI interface was used to ionize the 126 
compounds and analysis was performed both in positive and negative ionization mode. All 127 
pharmaceuticals were  analyzed using reversed phase chromatography, except for metformin 128 
and guanylurea which were analyzed using the HILIC column. Details on LC conditions and gradients 129 
are listed in the “Description of chemical analysis” of the Supplementary Information. The ratio of the 130 
responses of at least two mass transitions were used for positive identification of the individual 131 
compounds. The average response of these two masses was used for quantification and comparison 132 
with external calibration standards (Mezcua et al., 2009). All analysis were performed within one 133 
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analytical run and blanks and external standards were added every ten samples to monitor analytical 134 
performance. 135 
 136 
Limits of quantification were generally 0.01 µg/L, except for 4-acetaminophen sulphate, cortisol, 137 
cortisone and erythromicine A (all 0.025 µg/L), O-desmethyl naproxen, paroxetine, prednisolone, 138 
metformin and guanylurea (all 0.050 µg/L), norfluoxetine, hydroxy ibuprofen and ciprofloxacin (all 0.50 139 
µg/L) and salicylic acid (> 5.0 µg/L) . No corrections were made for recoveries as most recoveries of 140 
detected compounds were between 80 and 120 %. Details can be found in Table S2 of the 141 
Supplementary Information.  142 
 143 
Calculating emissions from monitoring data 144 
Flow rate data with a 15 min (Jeker, Geul, Geleenbeek) or 1 h (Meuse) interval were obtained from 145 
regional water authorities. Flow rates showed some scatter in time, therefore, the total water flow over 146 
a period of 24h (qday) at the sampling date was multiplied with the observed concentration of the 147 
pharmaceutical or TP (Cpharmaceutical)  to calculate the daily load (Qday): 148 
daycalpharmceutiday qCQ   eq.1
 149 
Furthermore, loads per inhabitant (Qinhab) were calculated to compare emissions of inhabitants from 150 
different regions according to:  151 
inhab
day
inhab
n
Q
Q 
  eq. 2 
152 
For the Slijbeek no flow rate data were available, so loads could not be calculated. 153 
 154 
Predicting emissions from sales data 155 
Sales data of pharmaceuticals in 2011 were obtained from the Dutch Foundation for Pharmaceutical 156 
Statistics (SFK) and the Belgian National Institute for Disease- and Disability-Insurance (RIZIV). It was 157 
assumed that the consumption of the inhabitants of the Geleenbeek and Geul catchment corresponded 158 
 8 
to the Dutch and combined Dutch and Belgian national average, respectively. This assumption seems 159 
valid since the sales of pharmaceuticals in the region that covers the Geleenbeek basin and the Dutch 160 
part of the Geul basin is near 100 % (106 %) of the Dutch average (van Batenburg-Eddes et al., 2002). 161 
For the Jeker catchment, regional sales data of 91,645 out of the 101,535 (Directorate General Statistics 162 
and Economic Information, 2013) inhabitants in 2011 were obtained. Here it was assumed that the 163 
consumption of the 10 % missing inhabitants was the same as for inhabitants of which sales data were 164 
obtained.  165 
 166 
Finally, for all catchments, it was assumed that all residents of the catchment discharge all their sewage 167 
via sewage treatment plants in their catchment of residence. This assumption might not always be 168 
correct since commuting, traveling (holidays) the use of septic tanks and emissions of untreated sewage 169 
can bias the actual discharge. There are however no suitable data to correct for these biases.  170 
 171 
Daily emitted loads (Qday-pred) were estimated using respective annual sales data (Qyear) of 2011, the 172 
fraction that passes the Sewage Treatment Plant (fSTP) and the excretion rate by humans (fraction of 173 
consumption excreted, fExcr) according to the following equation: 174 
STPExcr
year
predday ff
Q
Q 
365   eq.3
 175 
The STP removal rates and human excretion rates are listed in Table 2 en the Dutch and Belgian Qyear-176 
values are listed in Table S3 of the Supplementary Information.  Generic removal rates are used to 177 
predict emissions since there were no regional of STP-specific removal rates available. It should be 178 
noted that the number of inhabitants inhabitant in the Jeker catchment exceeded the inhabitant 179 
equivalents of the STPs due to insufficient capacity of the some treatment plants and the fact that not 180 
all wastewater is treated in STPs (SPGE, 2006). So the applied generic removal rates in Table 2 might 181 
overestimate actual removal of some pharmaceuticals for the Jeker catchment. 182 
 183 
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TABLE 2184 
 10 
Results and discussion 185 
 186 
Analytical results 187 
24 pharmaceuticals and 13 transformation products were observed in the surface waters. Figure 2 188 
shows the concentration ranges of the pharmaceuticals observed and the percentage of positive 189 
detections ( %)  in all samples.  190 
 191 
FIGURE 2 192 
 193 
The transformation product guanylurea and its parent pharmaceutical metformin show the highest 194 
concentrations in surface waters. Furthermore, high concentrations of transformation products such as 195 
hydroxy ibuprofen, transdiol carbamazepine,  acetaminophen sulphate and desmethyl tramadol are 196 
observed. These data show that transformation products can form a relevant proportion of the total 197 
pharmaceutical load of surface waters.  198 
 199 
Grab sampling 200 
Grab sampling during late autumn might not provide a representative ‘average’ sample since the 201 
emissions of STP show both daily and seasonal fluctuations in pharmaceutical emissions that are related 202 
to variations in consumption and treatment performance (ter Laak et al., 2010). The daily variations in 203 
pharmaceutical emissions in the Geul and Geleenbeek are likely of minor impact since samples were 204 
taken 25 to 34 km downstream of the STP effluents, which is roughly equivalent to 0.5 to 1.0 days 205 
residence time (Personal Communication, Harry Tolkamp, Roer en Overmaas Regional Water 206 
Authority). The length of the Jeker is 65 km and there are twenty STPs with a total capacity of just over 207 
100,000 inhabitant equivalents along its catchment. Additionally , ten STPs with a total capacity of 208 
approximately 35.000 to 40.000 I.E. are planned since various communities are not yet connected to 209 
sewage treatment and currently emit untreated wastewater into the Jeker (SPGE, 2006). Hence, for the 210 
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Geleenbeek, Geul and Jeker, sufficient mixing of the flow rates with relatively pristine river water had 211 
occurred before the actual sampling was performed. Contrastingly, the Slijbeek is fed by a single STP 212 
located only few km upstream from the sampling location. This sample can therefore be strongly 213 
influenced by daily fluctuations of concentrations of pharmaceuticals, so these data should be 214 
interpreted with care.  215 
 216 
Pharmaceuticals and transformation products in surface waters 217 
Figure 3 shows the ratios of the concentrations of the transformation products (TPs) versus its parent 218 
pharmaceutical (PP) on a molar basis for the  different rivers. The data of the Geul catchment (n=4) are 219 
excluded from the data shown in Figure 3 as concentrations of pharmaceuticals and/or transformation 220 
products were often close to limits of quantification, revealing less accurate ratios than for the other 221 
sampling locations. Constant ratios enable to estimate concentrations of transformation products from 222 
the concentration of the parent molecule or vice versa. 223 
 224 
FIGURE 3 225 
 226 
Metformin is excreted unchanged by humans (Van Loenen, 2008). Guanylurea is formed during sewage 227 
treatment (Scheurer et al., 2009; Scheurer et al., 2012; Oosterhuis et al., 2013). Likely, similar processes 228 
occur in surface waters. However, there are no studies that have illustrated and quantified 229 
metformin break down rates in the aqueous environment. There is only sparse circumstantial 230 
evidence that suggests that rates in the environment are much lower than in STPs (Oosterhuis 231 
et al., 2013). Additional information on environmental degradation of this compound is 232 
required to improve predictions on its environmental fate. 233 
 234 
A study of eight Dutch sewage treatment plants revealed that  53 % to 98  % of metformin is removed 235 
during treatment (Vergouwen et al., 2011). Furthermore, Oosterhuis et al (2013) reported up to 99 % 236 
metformin removal by secondary treatment with a membrane bioreactor and that 91 % and 85% of the 237 
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metformin in the influent was recovered  as guanylurea in the STP effluent and receiving water, 238 
respectively.  239 
 240 
The current data show a large variation in the ratio of metformin and guanylurea in surface waters. The 241 
average TP/PP ratio for these compounds is 8.7 with a 95 % confidence interval of 1.2 to 16.4 (n=16). 242 
Large differences are observed between and within rivers (Figure 3). The TP/PP ratio in the Slijbeek, 243 
that is fed by a single Dutch STP varied from 3.4 to 40.1. Similar observations were made in the 244 
Geleenbeek that is fed by three Dutch STPs. The samples taken from the river Meuse at Eijsen (Belgian-245 
Dutch border) and Jeker that are fed by Belgian sewage effluents show much lower TP/PP ratios of 0.55 246 
± 0.28. 247 
 248 
For both the Geleenbeek and Slijbeek a clear difference in TP/PP ratio of metformin and guanylurea 249 
between the end of dry period (first two samples) and wet period (last two samples) was observed. In 250 
the dry period the average TP/PP ratio was 30.1 with a standard deviation of ± 14.8 (n=4) and in the  251 
wet period  a significantly lower TP/PP ratio of 3.7 with a standard deviation of ± 2.5 (n=4) was 252 
observed (T-test, p-value 0.013). The river Meuse and Jeker samples also show significantly different 253 
ratios during dry and wet conditions as well (0.77 ± 0.20 and 0.33 ± 0.11  respectively, T-test, p-value 254 
0.007). Possibly rainfall events, that increase flow of wastewater and reduce hydraulic retention times 255 
in treatment plants, and slightly lower temperatures during the last two sampling dates (surface water 256 
temperature 7.6 to 8.7 °C vs. 8.3 to 10.1 °C) affected the metformin transformation into guanylurea. 257 
 258 
This illustrates that the removal of metformin and the formation of guanylurea varies between rivers 259 
(or STPs) and with environmental conditions. The limited number of samples and variable ratios do not 260 
allow for a reliable estimation of concentrations of the transformation products from analysis of the 261 
parent molecule.  262 
 263 
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For carbamazepine, four human metabolites were observed in the surface waters. Interestingly, the 264 
molar ratios of the TPs and PP is similar within and between different surface waters (Figure 3).  The 265 
TP/PP ratio of 10,11-trandiol carbamazepine is 2.7 with a narrow 95 % confidence interval of 2.6 to 2.9 266 
(n=15).  The average TP/PP ratios of the 3-hydroxy carbamazepine, 2-hydroxy carbamazepine and  267 
epoxy carbamazepine are 0.20 (95 % CL 0.18 to 0.22, n=15), 0.17 (95 % CL 0.15 to 0.18, n=15) and 0.12 268 
(95 % CL 0.11 to 0.13, n=15), respectively. Figure 4 illustrates the fraction of the consumed 269 
carbamazepine that can be retrieved as parent pharmaceutical and the abovementioned 270 
transformation products in the surface water of two catchments.  271 
 272 
FIGURE 4 273 
 274 
Fractions of carbamazepine and transformation products recovered in surface waters appear to be 275 
slightly lower but show a strikingly similar pattern to the fractions of these metabolites excreted in 276 
urine (Eichelbaum et al., 1985). The excretion of 10,11-transdiol carbamazepine in mono-therapy and 277 
therapy combined with other anticonvulsants ranges from 26.5 to 49.9 % of the consumed amount. In 278 
this study 20.2 to 31.5 % of the consumed carbamazepine could be recovered as 10,11-transdiol 279 
carbamazepine in surface waters. The excretion of 3-hydroxy carbamazepine in urine is 3.0 to 4.2 %, 280 
while 1.6 to 2.0 % was recovered surface waters in this study. For 2-hydroxy carbamazepine these 281 
values amounted to 2.4 to 3.1 % vs. 1.2 to 2.0 %, and for epoxy carbamazepine 1.1 to 1.5 % vs. 0.8 to 282 
1.3 %.   283 
 284 
Renal excretion rates of carbamazepine and its transformation products is well studied (Eichelbaum et 285 
al., 1985), but the composition of the fraction that is excreted via feces is (to our knowledge) unknown. 286 
In this study 6.3 to 10.3 % of the consumed carbamazepine amount  is recovered in receiving surface 287 
waters. The recalcitrance of carbamazepine in the sewage treatment and environment (Heberer, 2002) 288 
and the stable ratios of the various transformation products that largely correspond to renal excretion 289 
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suggest that the metabolites are also recalcitrant in sewage treatment and the environment. These 290 
constant ratios allow for highly accurate estimation of concentrations of the transformation products 291 
from analysis of the carbamazepine and vice versa. 292 
 293 
The ratio of tramadol and the human metabolite O-desmethyl tramadol  observed in surface waters in 294 
the present study is constant. The average TP/PP ratio for these compounds is 0.55 with a 95 % 295 
confidence interval of 0.49 to 0.62 (n=14). This is very similar to ratios observed in surface waters of 296 
earlier studies (de Jongh et al., 2012) and  fall within ratios observed in human urine  that range from 297 
0.26-0.75 (Lintz et al., 1981; Ardakani Y. H. and R., 2009; Chitil et al., 2009). Apparently, both tramadol 298 
and O-desmethyl tramadol are rather recalcitrant and stable ratio is retained in the urban water cycle. 299 
This stable ratio enables one to accurately estimate concentrations of O-desmethyl tramadol  from 300 
analysis of tramadol  and vice versa. 301 
 302 
The average TP/PP ratio of α-hydroxy metoprolol is 0.15 with a 95 % confidence interval of 0.11 to 0.20 303 
(n=11). This ratio is slightly lower than the observed metabolic ratio of 3.1 ± 2.5  that equals a TP/PP 304 
ratio of 0.32 (Tu and Zhao, 1995). Minor differences might be explained by either higher removal of α-305 
hydroxy metoprolol during sewage treatment or additional metoprolol excretion via feces that was not 306 
accounted for in the cited study. The average TP/PP of sulfamethoxazole and its product N4-acetyl 307 
sulfamethoxazole observed in amounts to 0.66 with a 95 % confidence interval of 0.42 to 0.89 (n=15). 308 
This TP/PP is one fifth of the reported human excretion ratio of 3.15 (Lienert et al., 2007). Possibly, the 309 
acetylated sulfamethoxazole is partially removed or transformed during sewage treatment processes 310 
and in surface water. Partial removal or transformation during sewage treatment (Verlicchi et al., 2012) 311 
might explain why the TP/PP of metoprolol and sulfamethoxazole and their respective human 312 
metabolites show more variation than carbamazepine and tramadol. Unfortunately, there are, to our 313 
knowledge, no literature data on STP removal rates of the metabolites to verify this hypothesis. 314 
Nevertheless, the TP/PP of sulfamethoxazole and metoprolol appear rather stable and allow to 315 
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estimate concentrations of the transformation products from analysis of the parent molecule and vice 316 
versa within a factor of two. 317 
 318 
Apparently, the average metabolism of pharmaceuticals by a large population of humans is stable while 319 
transformation and sorption processes further down the urban water cycle result in more variable 320 
removal rates for some pharmaceuticals. Considering this observation, it is relevant to investigate 321 
temperature, oxygen concentration, combination of oxic and anoxic conditions, redox potential, 322 
residence time in various treatment processes, composition of the water, applied treatment techniques 323 
(composition of) biodegraders in active sludge and adsorption processes  on the removal of 324 
pharmaceuticals during sewage treatment (Onesios et al., 2009; Pomiès et al., 2013). The TP/PP ratio 325 
might be a suitable parameter to monitor such processes and reveal parameters that affect  326 
transformation rates. Finally, the potential risks of both parent pharmaceuticals and transformation 327 
products need to be assessed for a proper environmental risk assessment.  328 
 329 
Loads of pharmaceuticals and transformation products 330 
Loads were calculated for all pharmaceuticals and transformation products that were observed during 331 
all four sampling dates.  332 
 333 
FIGURE 5 334 
 335 
The loads are predicted by multiplying the consumed pharmaceuticals by the predicted fraction 336 
excreted by the user and the fraction remaining during STP passage (Eq. 3 and Table 2), as discussed in 337 
the paragraph “Calculating emissions from monitoring data” above (ter Laak et al., 2010). Figures 5a-c 338 
show the observed daily loads of pharmaceuticals versus the predicted loads. Not all observed 339 
pharmaceuticals listed in Figure 2 were included since for some of these either Dutch  or  Belgian  sales 340 
data were lacking.  341 
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 342 
Figures 5a-c show that for some pharmaceuticals the measured loads exceed predicted loads at one or 343 
more locations. The largest of these underestimations are observed for the analgesic / anti-344 
inflammatory pharmaceuticals naproxen, ketoprofen and paracetamol. These underestimations are 345 
likely explained by additional ‘over the counter’ sales that are not registered by the Belgian and Dutch 346 
monitoring organizations since they are not only sold and documented by official pharmacies nor 347 
reimbursed by health insurance. Furthermore, the actual load of the lipid regulator gemfibrozil, is 348 
underestimated by a factor three in both the Geleenbeek and Geul . There is no obvious explanation for 349 
this underestimation. Gemfibrozil is, however, known to be excreted in conjugated forms (Dix et al., 350 
1999). Potentially these conjugates are de-conjugated during sewage treatment and in the 351 
environment, resulting in higher loads of the parent pharmaceutical in receiving waters. Finally, 352 
lincomycin, a lincosamide antibiotic, shows a higher concentration in the Jeker than predicted from 353 
human consumption. Lincomycin is also used in veterinary practice, so emissions from veterinary use in 354 
the Jeker catchment potentially resulted in additional loads in the river.  355 
 356 
Carbamazepine and three antibiotics (sulfamethoxazole, erythromycin A and metronidazole) show a 2 357 
to 4 fold lower concentration than predicted from sales. The overestimation of  the concentrations of 358 
the antibiotics might be related to uncertainties in the reported removal rates by sewage treatment or 359 
metabolism, since the removal in these to processes is both relevant (Table 2). The consistent factor 360 
overestimation of carbamazepine concentrations cannot be explained by uncertainties in reported 361 
removal rates because carbamazepine is very persistent in sewage treatment and the environment 362 
(Clara et al., 2004). Oosterhuis (2013) monitored carbamazepine concentrations in sewage influent, 363 
effluent and receiving surface waters and compared these to their local sales data.  A similar 364 
overestimation was observed in this study, (Oosterhuis et al., 2013). The predicted environmental loads 365 
calculated in both studies are based upon excretion rates obtained from Lienert et al (Lienert et al., 366 
2007). Lienert justly discusses the relevance of fecal excretion of carbamazepine for emissions into the 367 
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environment, a factor that is often neglected in pharmacological studies. There is, however, no data 368 
supporting the assumption that the fecal excretion is solely as parent pharmaceutical. The observed 369 
loads in the surface waters and ratio with transformation products in the present study suggest that the 370 
total excretion of non-metabolized carbamazepine is rather around 10 % than the 26 % proposed by 371 
Lienert et al. or the 1 to 3 % found in urine (Lienert et al., 2007). However, additional studies are 372 
required to test this hypothesis. 373 
 374 
In this study the discrepancies between observed and predicted loads are a result of analytical 375 
uncertainties (small), uncertainties introduced by grab sampling (variable, depends on sampling 376 
location and sampling date and time), regional variation in consumption (generally small within 377 
countries, larger between countries), seasonal variations in consumption (relevant for some 378 
pharmaceuticals), uncertainties in sales data (relevant for some pharmaceuticals), transformation and 379 
excretion rates (relevant for some pharmaceuticals, fecal excretion is generally studied less) variations 380 
in removal efficiencies of sewage treatment (can strongly vary within and between treatment plants). 381 
Discrepancies in the order of a factor three are therefore likely to be observed (Alder et al., 2010; ter 382 
Laak et al., 2010). Local data on consumption, excretion and treatment specific removal rates as well as 383 
improved sampling during different seasons can increase the accuracy of the prediction to some extent, 384 
but a certain degree of uncertainty will remain.  385 
 386 
Per capita emission of pharmaceuticals and transformation products 387 
The loads of the pharmaceuticals and transformation products present in all datasets are normalized 388 
per inhabitant and presented in Figure 6. The data illustrate that the per capita load of pharmaceuticals 389 
is higher for the Geul and Jeker compared to the Geleenbeek catchment. The per capita loads of the 390 
Slijbeek were not calculated since there were no flow rate data available. The loads in the river Meuse 391 
were not calculated because loads can’t be directly linked to sales, since this is a complex water system 392 
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with variable flow rates between the river Meuse and various canals that are fed by the river Meuse 393 
and circumvent the sampling location at the Belgian-Dutch border.  394 
 395 
FIGURE 6 396 
 397 
Comparing per capita emissions  from Belgium and the Netherlands 398 
The Geul and Jeker showed a significantly higher per capita load of pharmaceuticals and transformation 399 
products than Geleenbeek (Figure 6). The Geul and Jeker (also) transport effluents from Belgian origin. 400 
This suggests that more pharmaceuticals are used in Belgium and/or that removal by sewage treatment 401 
in the Belgian part of the catchment is less efficient or not present (SPGE, 2006). The Geleenbeek and 402 
Jeker were selected for a more detailed comparison, since the Geul is fed by both Dutch and Belgian 403 
sewage effluents which might result in ambiguous data. 404 
 405 
FIGURE 7 406 
 407 
In Figure 7  per capita loads of the Belgian (Jeker) and Dutch (Geleenbeek) populations are plotted 408 
against each other. Since most of the data points in Figure 7 are situated at the right hand side of the  409 
1:1 line (diagonal in Figure 7), most pharmaceuticals and transformation products show a higher per 410 
capita load from the Belgian population. This corresponds to higher total per capita loads shown in 411 
Figure 6. Only a few pharmaceuticals and transformation products show higher per capita loads from 412 
the Dutch population. Part of the differences in per capita loads can be explained by differences in 413 
pharmaceutical consumption in Belgium and the Netherlands. For example, Dutch per capita sales of 414 
metoprolol are eight times higher than Belgian sales (SFK & RIZIV). This is reflected in the higher per 415 
capita load of both metoprolol and α-hydroxy metoprolol in the Geleenbeek. Furthermore, the two fold 416 
higher per capita load of furosemide in the Geleenbeek compared to the Jeker also corresponds to 417 
differences in sales in the Netherlands and Belgium (SFK & RIZIV). Finally, the absence of the lipid 418 
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regulator gemfibrozil in waters originating from Belgium (Meuse and Jeker) can be explained by the fact 419 
that it is not prescribed and reimbursed in Belgium (Belgian Centre for Farmacotherapeutic Information 420 
CFI, 2014).  421 
 422 
On the other hand, the per capita loads of metformin, tramadol and its de-methylated transformation 423 
product, venlafaxine, naproxen, paracetamol, propranolol, ketoprofen and metronidazole exceed the 424 
Dutch per capita load over a factor three. For propranolol, tramadol and venlafaxine, the higher per 425 
capita loads can be explained by higher consumption in Belgium. Contrastingly, the consumption of 426 
metformin is very similar in both countries (SFK en RIZIV). Probably the higher per capita load of 427 
metformin is explained by absence or less efficient of treatment of part of the Belgian sewage. This 428 
hypothesis is supported by the lower formation of guanylurea/metformin ratioin waters from Belgium 429 
(see paragraph “Pharmaceuticals and transformation products in surface waters”). The higher per 430 
capita loads for the analgesics and anti-inflammatory pharmaceuticals ketoprofen, naproxen, 431 
paracetamol and ibuprofen (hydroxy ibuprofen is detected) are more difficult to explain from sales data 432 
since part of these pharmaceuticals are sold ‘over the counter’ without being registered.  433 
 434 
Implications 435 
The current study illustrates that there are regional differences in pharmaceutical loads and 436 
concentrations in different catchments can be related to differences in sales patterns and absence of 437 
sewage treatment. A better understanding of the relation between consumption, excretion processes 438 
and removal or transformation efficiencies of STPs, emissions and further dilution, sorption and 439 
transformation in rivers and river systems enables to optimize use of (limited) monitoring activities. For 440 
example, relations between the occurrence of pharmaceuticals and transformation products and 441 
potentially even between different pharmaceuticals or between sales data and occurrence data can 442 
extend the application of monitoring data. Furthermore, knowledge on transformation processes and 443 
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transformation products generated in sewage treatment also enables one to monitor and  potentially 444 
interpret sewage treatment efficiency and further transformation in surface waters.  445 
 446 
Conclusions 447 
 Transformation products represent a relevant fraction of the total concentration of 448 
pharmaceuticals in surface waters 449 
 Stable ratios between pharmaceuticals and their transformation products allow estimation of 450 
concentrations from one to the other 451 
 Variable ratios of metformin and guanylurea might be applied as an indicator of sewage 452 
treatment performance and discharge of untreated sewage 453 
 Sales data, excretion from the body and removal in STPs can be used to estimate loads in 454 
surface waters for most pharmaceuticals 455 
 per capita loads of most pharmaceuticals from Belgium are significantly higher than those from 456 
the Netherlands 457 
 Information on (regional) sales or consumption of pharmaceuticals and transformation 458 
products can provide a better qualitative and quantitative understanding of their occurrence in 459 
surface waters 460 
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Figure captions 473 
Figure 1: Sampling locations. Slijbeek (1), Geleenbeek (2), Geul (3), Jeker (4) and Meuse at the Belgian- 474 
Dutch border (5) 475 
 476 
Figure 2: Box/whisker plots of the concentration ranges and detection frequency of pharmaceuticals 477 
and transformation products in all surface water samples (n=20). The boxes represent the 25 to 75 478 
percentile with the median value indicated in the center, the whiskers give maximum and minimum 479 
values. 480 
 481 
Figure 3: Box/whisker plots of the molar ratio between concentration of transformation products (TP) 482 
and their parent pharmaceutical (PP) in surface waters (TP/PP).  For each location four samples were 483 
used. The exceptions are; carbamazepine ratios in de Meuse (n=3), tramadol ratios in the Slijbeek and 484 
Meuse (n=3), metoprolol ratios in the Jeker (n=3) and Meuse (n=0) and sulfamethoxazole ratios in the 485 
Slijbeek (n=3). The boxes represent  median and 25 and 75% and the whiskers give maximum and 486 
minimum values. 487 
The following abbreviations are used in the figure: MET = metformin,  GA = guanylurea, CBZ = 488 
carbamazepine, 10,11-DiOH CBZ = 10,11-trans diol carbamazepine, 3-OH CBZ = 3-hydroxy 489 
carbamazepine, 2-OH CBZ = 2-hydroxy carbamazepine, epoxy CBZ = epoxy carbamazepine, SMZ = 490 
sulfamethoxazole,  N4-AC SMZ = N4-acetyl  sulfamethoxazole , TRM = tramadol, O-DM TRM = O-491 
desmethyl tramadol, MTL = metoprolol and α-OH MTL =  α-hydroxy metoprolol. 492 
 493 
Figure 4: Fraction of the sold carbamazepine retrieved in surface water of the Jeker and Geleenbeek 494 
 495 
Figure 5a-c: Measured vs. predicted loads of pharmaceuticals for the Geleenbeek (a) Jeker (b) and Geul 496 
(c) catchment. The solid line represents the 1:1 relation and the dashed lines are the 1:3 and 3:1 497 
relation of measured and predicted loads. The error bars represent standard deviations   498 
 499 
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Figure 6: Box/whisker plots of the daily load per inhabitant with (A) and without (B) metformin and 500 
guanlyurea.  It should be noted that metformin and its transformation product account for 53 to 79 % 501 
of the total load in the abovementioned rivers. The figure only depicts the pharmaceuticals that were 502 
observed in 100 % of all samples of the tributaries. The broken lines indicate statistical differences (T-503 
test p-value <0.01) between the values of the Geleenbeek and the Geul and the Geleenbeek and the 504 
Jeker. No statistical differences between Geul and Jeker were observed (p-value > 0.05). 505 
 506 
Figure 7: Per capita loads of pharmaceuticals, the Geleenbeek from the Netherlands vs. the Jeker from 507 
Belgium. The solid line represents the 1:1 relation and the dashed lines are the 1:3 and 3:1 relation of 508 
measured and predicted loads. The error bars represent standard deviations   509 
 510 
literature of figures, do not include these lines  in the manuscript, it is solely used to correctly update the 511 
literature list using Endnote   512 
(SPGE, 2006; Van Loenen, 2008; RIWA Maas, 2009) (Carr et al., 1992) (Lienert et al., 2007) (Ardakani Y. 513 
H. and R., 2009) (Prescott, 1980) (Howell et al., 1993) (European Medicines Agency, 1998) (Lamp et al., 514 
1999) (Vergouwen et al., 2011) (Wick et al., 2009) (Castiglioni et al., 2006) (Radjenovic et al., 2007) (Rúa-515 
Gómez and Püttmann, 2012) (Radjenovic et al., 2007) (Miege et al., 2009) (Watkinson et al., 2007) (Rosal 516 
et al., 2010) (European Medicines Agency, 1997; Grubb et al., 1999)  517 
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